Article Data

  • Views 199
  • Dowloads 149

Original Research

Open Access

Expression of E-cadherin in primary endometrial carcinomas: clinicopathological and immunohistochemical analysis of 30 cases

  • M. Varras1,*,
  • E. Skafida2
  • T. Vasilakaki2
  • A. Anastasiadis1
  • C. Akrivis3
  • N. Vrachnis4
  • G. Nikolopoulos5

1Third Department of Obstetrics and Gynecology, “Elena Venizelou” General Maternity State Hospital, Athens

2Department of Pathology, “Tzaneio” General State Hospital, Piraeus

3Department of Obstetrics and Gynecology, “G. Chatzikosta” General State Hospital, Ioannina

4Second Department of Obstetrics and Gynecology, University of Athens, Athens

5,Hellenic Centre for Diseases Control and Prevention (Greece).

DOI: 10.12892/ejgo340104 Vol.34,Issue 1,January 2013 pp.31-35

Published: 10 January 2013

*Corresponding Author(s): M. Varras E-mail: mnvarras@otenet.gr

Abstract

Introduction: Decreased expression of E-cadherin has been associated with poorly differentiated endometrial carcinomas and poorer outcomes. Aim: The purpose of this study was to examine the distribution of E-cadherin immunohistochemical expression in specimens from primary endometrial carcinomas and its relation to classical clinicopathological prognostic factors. Materials and Methods: Surgically-resected tissues of 30 patients with primary endometrial carcinomas were studied. Histological type and grade, depth of myometrial invasion, lymph-vascular space invasion, fallopian tube or ovarian invasion, and the presence of tumoral necrosis were evaluated. Immunohistochemical examination was performed on deparaffinized four-µm-thick sections. Results: The mean age of patients was 65 years (± 11.41). The 63.54% of carcinomas were moderately/poorly differentiated. No statistical correlation was found between the score or intensity of E-cadherin immunohistochemical staining (strong or moderate positive expression) and the clinicopathological factors tested. Conclusions: The association of E-cadherin immunoreactivity with the standard clinicopathological factors seemed to be contradictory. The classical clinicopathological factors remain the most important prognostic parameters.

Keywords

E-cadherin; Carcinoma; Endometrial; Endometrioid; Immunohistochemistry; Pathology.

Cite and Share

M. Varras,E. Skafida,T. Vasilakaki,A. Anastasiadis,C. Akrivis,N. Vrachnis,G. Nikolopoulos. Expression of E-cadherin in primary endometrial carcinomas: clinicopathological and immunohistochemical analysis of 30 cases. European Journal of Gynaecological Oncology. 2013. 34(1);31-35.

References

[1] Yalta T., Atay L., Atalay F., Caydere M., Gonultas M., Ustun H.: “E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas”. J. Int. Med. Res., 2009, 37, 163.

[2] Ascaño J.J., Frierson H. Jr., Moskaluk C.A., Harper J.C., Roviello F., Jackson C.E. et al.: “Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer”. Mod. Pathol., 2001, 14, 942.

[3] Holcomb K., Delatorre R., Pedemonte B., McLeod C., Anderson L., Chambers J.: “E-cadherin expression in endometrioid, papillary serous and clear cell carcinoma of the endometrium”. Obstet. Gynecol., 2002, 100, 1290.

[4] Liu Fu-Shing: “Molecular carcinogenesis of endometrial cancer”. Taiwanese J. Obstet. Gynecol., 2007, 46, 26.

[5] Sakuragi N., Nishiya M., Ikeda K., Ohkouch T., Furth E.E., Hareyama H. et al.: “Decreased E-cadherin expression in endometrial carcinoma is associated with tumor dedifferentiation and deep myometrial invasion”. Gynecol. Oncol., 1994, 53, 183.

[6] Ohashi M., Kusumi T., Sato F., Kudo Y., Jin H., Akasaka H. et al.: “Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient’s prognosis and recurrent status of extrahepatic bile duct carcinoma”. Biomed. Res., 2009, 30, 79.

[7] Scholten A.N. Aliredjo R., Creutzberg C.L., Smit V.T.: “Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favourable prognostic factor in endometrial carcinoma”. Int. J. Gynecol. Cancer, 2006, 16, 1379.

[8] Mell L., Meyer J., Tretiakova M., Khramtsov A., Gong C., Yamada D.S. et al.: “Prognostic significance of E-cadherin protein expression in pathological Stage I-III endometrial cancer”. Clin. Cancer Res., 2004, 10, 5546.

[9] Horner M.J., Ries L.A.G., Krapcho M., Neyman N., Aminou R., Howlader N., et al. (eds). “SEER Cancer Statistics Review 1975- 2006, National Cancer Institute”. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.

[10] Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., Graham J.E.: “Relationship between surgicalpathological risk factors and outcome in clinical Stage I and II carcinoma of the endometrium: a Gynecology Oncology Group study”. Gynecol. Oncol., 1991, 40, 55.

[11] Kadar N., Homesley H.D., Malfetano J.H.: “Prognostic factors in surgical Stage III andv IV carcinoma of the endometrium”. Obstet. Gynecol., 1994, 84, 983.

[12] Zhou Y.N., Xu C.P., Han B., Li M., Qiao L., Fang D.C., Yang J.M.: “Expression of E-cadherin and β-catenin in gastric carcinoma and its correlation with clinicopathological features and patient survival”. World J. Gastroenterol., 2002, 8, 987.

[13] Laza˘r D., Ta˘ban S., Ardeleanu C., Dema A., Sporea I., Cornianu M. et al.: “The immunohistochemical expression of E-cadherin in gastric cancer; correlations with clinicopathological factors and patients’ survival”. Rom. J. Morphol. Embryol., 2008, 49, 459.

[14] Joo Y.E., Park C.S., Kim H.S., Choi S.K., Rew J.S., Kim S.J.: “Prognostic significance of E-cadherin/catenin complex expression in gastric cancer”. J. Korean Med. Sci., 2000, 15, 655.

[15] Schmalhofer O., Brabletz S., Brabletz T.: “E-cadherin, β-catenin, and ZEB1 in malignant progression”. Cancer Metastasis. Rev., 2009, 28, 151.

[16] Jawhari A., Farthing M., Pignatelli M.: “The importance of E-cadherin-catenin complex in the maintenance of intestinal epithelial homeostasis: more than intercellular glue”. Gut, 1997, 41, 581.

[17] Bansal N., Yendluri V., Wenham R.M.: “The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies”. Cancer Control., 2009, 16, 8.

[18] Ashida K., Terada T., Kitamura Y., Kaibara N.: “Expression of Ecadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study”. Hepatology, 1998, 27, 974.

[19] Perl A.K., Wilgenbus P., Dahl U., Semb H., Christofori G.: “A causal role for E-cadherin in the transition from adenoma to carcinoma”. Nature, 1998, 392, 190.

[20] Stemmer V., de Craene B., Berx G., Behrens J.: “Snail promotes Wnt target gene expression and interacts with beta-catenin”. Oncogene, 2008, 27, 5075.

[21] Peinado H., Portillo F., Cano A.: “Transcriptional regulation of cadherins during development and carcinogenesis”. Int. J. Dev. Biol., 2004, 48, 365.

[22] Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, Takano S, Miyazaki M.: “Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients”. Br. J. Cancer, 2006, 94, 1816.

[23] Singh M., Spoelstra N.S., Jean A., Howe E., Torkko K.C., Clark H.R. et al.: “ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease”. Mod. Pathol., 2008, 21, 912.

[24] Blechschmidt K., Kremmer E., Hollweck R., Mylonas I., Höfler H., Kremer M., Becker K.F.: “The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas”. Diagn. Mol. Pathol., 2007, 16, 222.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top